Velindre Cancer Centre

Recent papers from Velindre Cancer Centre

1. Artificial intelligence approaches for early prediction and risk stratification of immune checkpoint inhibitor-related myocarditis: a systematic reviewEuropean Heart Journal Supplements · 2026
2. Precision Cardio-Oncology: A Multimodal Approach to Cancer Therapy-Related Cardiovascular Toxicity Prediction and AssessmentCancers · 2026
3. Prognostic significance of EGFR-1 and VEGF-A expression in feline cutaneous squamous cell carcinomaFrontiers in Veterinary Science · 2026
4. A UK Delphi consensus study on the definition and management of advanced cutaneous squamous cell carcinomaFuture Oncology · 2026
5. Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix TrialClinical Cancer Research · 2026
6. 55 Radiotherapy Peer Review in Neuro-Oncology: National Survey of Practice, Barriers and AI IntegrationNeuro-Oncology · 2026
7. 28 Travel time and carbon footprint of patients accessing stereotactic radiosurgery for intracranial metastatic disease from South West WalesNeuro-Oncology · 2026
8. Tolerability, dose modification, and treatment compliance with adjuvant abemaciclib in high-risk early breast cancer: a UK real-world multicentre study (CONCISE)ESMO Real World Data and Digital Oncology · 2026
9. Embarking on a new era in high-risk biochemical recurrent prostate cancer: redefining early systemic interventionPharmacology & Therapeutics · 2026
10. IUC26658-92 Efficacy Patterns of First-Line Immune Checkpoint Inhibitor Combinations in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis Evaluating Ethnic VariationsThe Oncologist · 2026
11. IUC26692-90 Benchmarking Artificial Intelligence-Based Clinical Prediction Models for Immune Checkpoint Inhibitor Response and Overall Survival in Bladder CancerThe Oncologist · 2026
12. Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-derived external control armsJNCI Journal of the National Cancer Institute · 2026
13. Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast CancerJAMA Oncology · 2026
14. Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trialThe Lancet Oncology · 2026
15. A systematic review of heterogeneity in clinical trial design for anal cancer radiotherapy-immunotherapy combinationsClinical and Translational Radiation Oncology · 2026
16. Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B TrialEuropean Urology · 2026
17. Prognostic impact of anal cancer morphology on survival and local recurrence: A 20‐year regional cohort studyColorectal Disease · 2026
18. BNT326-01: A Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig (anti-PD-L1 × VEGF bsAb) in patients with advanced solid tumors.Journal of Clinical Oncology · 2026
19. HER2-positive central nervous system (CNS) surveillance: A study of the feasibility of randomizing women and men with HER2-positive metastatic breast cancer to CNS surveillance versus no surveillance.Journal of Clinical Oncology · 2026
20. Utilisation of the Henry score in malignant bowel obstruction and characterisation of management approaches and outcomes: Experience from a New Zealand regional centre.Journal of Clinical Oncology · 2026